There is a general consensus among clinicians that a serum prostate-specific antigen (PSA) level ≥4.0 ng/ml is predictive of prostate cancer, and necessitates a biopsy. But there is a dearth of ...

To perform prostate cancer biopsies, doctors use a technology called MRI fusion-guided biopsy. This technique combines MRI with a transrectal ultrasound to more precisely sample prostate tissue ... 46 ...

Targeted biopsy only (ignoring systematic samples ... whom underwent prostate biopsy. The patients had a median age of 65 and median prostate-specific antigen (PSA) level of 6.9 ng/mL.

A transperineal biopsy is a needle biopsy to look for cancer cells in the prostate. This helps to diagnose prostate cancer. Your doctor puts a needle into the prostate through the skin behind the ...

in blood samples. Prostate cancer spreads by shedding CTCs into the bloodstream, so higher counts in blood generally reflect worse disease. Sometimes referred to as a liquid biopsy, the CTC assay ...

11.7% had a polygenic risk score in the 90th percentile or higher and were invited to undergo screening. Of these participants, 62.8% underwent MRI and prostate biopsy. Median age at diagnosis was 64.

Of these 745 participants, 468 (62.8%) underwent MRI and prostate biopsy; prostate cancer was ... (weighted average percentage, 15.6%; range, 7.0 to 21.0) would have had overdiagnosed cancer ...

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many ...

Your doctor might take samples of tissue from the prostate during this test. This is a TRUS guided biopsy. It can help to diagnose prostate cancer. You usually have an MRI scan before your TRUS guided ...

Ultimately, 678 men underwent biopsy. Gleason Grade Group 2 or higher prostate cancer was detected in 47.1% of the microultrasonography group, 42.6% of the ... negative, and 7 cases were ...